Rett Syndrome

🧠 Standard of Care & Symptoms

Rett Syndrome is a progressive, X-linked neurodevelopmental disorder that almost exclusively affects females, leading to severe cognitive, motor, and autonomic regression.

• Presentation: Normal early growth followed by rapid developmental loss.
  • Developmental Regression: Infants typically develop normally for the first 6 to 18 months. This is followed by a sudden **regression phase**, during which they lose acquired purposeful hand skills (such as grasping or feeding) and spoken language.
  • Hand Stereotypies: The loss of purposeful hand movement is replaced by continuous, involuntary, stereotypic movements, including **hand wringing, washing, clapping, or mouthing**.
  • Neurological Deficits: Deceleration of head growth leading to **acquired microcephaly**, progressive gait ataxia (a stiff, wide-based, or shuffling walk), tremors, and scoliosis.
  • Autonomic Dysfunction: Characterized by severe breathing irregularities when awake, including hyperventilation alternating with prolonged breath-holding (**apnea**). Cold extremities and cardiac conduction delays (long QT interval) are also common.

🧬 Diagnostics & MECP2 Transcriptional Silencing

Diagnosis is established clinically based on the consensus diagnostic criteria and supported by molecular genetic testing of the MECP2 gene.

• Clinical Criteria: Requires the presence of a regression phase followed by recovery or stabilization, alongside major criteria: partial or complete loss of purposeful hand skills, loss of spoken language, gait abnormalities, and stereotypic hand movements.
• Genetic Testing: Confirms a pathogenic mutation in the X-linked **MECP2** gene. MECP2 mutations are lethal in most male fetuses, explaining the female predominance.

Pathogenesis & MeCP2 Epigenetic Regulation

The neurological regression in Rett Syndrome is driven by chromatin-mediated gene dysregulation:

• MECP2 Gene: Located on chromosome Xq28, it encodes **MeCP2** (methyl-CpG-binding protein 2), an essential epigenetic regulator abundant in mature neurons.
• Epigenetic Reader Function: MeCP2 selectively binds to methylated CpG dinucleotides on DNA. Once bound, it acts as a molecular hub, recruiting chromatin-remodeling complexes (such as **Sin3A** and **Histone Deacetylases (HDACs)**). These enzymes remove acetyl groups from histones, causing chromatin condensation (wrapping tightly) and silencing gene transcription. MeCP2 can also activate transcription depending on the cellular context.
• Downstream Targets (BDNF): Devoid of functional MeCP2, transcriptional control is lost, dysregulating thousands of downstream neurodevelopmental genes. Crucially, **brain-derived neurotrophic factor (BDNF)** expression is suppressed. This leads to severe dendritic arborization deficits (dendritic pruning), loss of synaptic plasticity, and a failure of neuronal maturation in the cortex and brainstem.

💊 Targeted Trofinetide & Multidisciplinary Care

Management requires a comprehensive program combining targeted pharmacotherapy, seizure management, and communication support.

Targeted Medical Therapy

• Trofinetide: Approved in 2023. Trofinetide is an oral synthetic analogue of **glycine-proline-glutamate (GPE)**, the naturally occurring amino-terminal tripeptide of IGF-1. Trofinetide crosses the blood-brain barrier and works by reducing neuroinflammation (by suppressing microglial and astrocytic overactivation) and restoring synaptic signaling, showing significant improvements in communication and motor skills.

Symptomatic and Supportive Care

• Antiepileptic Drugs: Prescribed to control seizures, which occur in > 80% of patients. Common choices include Valproic Acid, Lamotrigine, or Levetiracetam.
• Therapy and Communication: Physical therapy to prevent joint contractures and manage scoliosis; occupational therapy to optimize hand function; and speech therapy using eye-gaze tracking communication boards to establish non-verbal language.

🔬 Active Clinical Trials

Clinical trials are currently evaluating long-term trofinetide safety, gene replacement therapy using adeno-associated virus vectors to deliver functional MECP2 genes, and wearable breathing monitors.

🗺️ Next Steps After Diagnosis

If your child has recently been diagnosed with Rett Syndrome, coordinate these clinical pathways:

1. Verify MECP2 Gene Mutation: Complete genetic screening to confirm the specific mutation type (missense, nonsense, or deletion).
2. Consult a specialized Neurodevelopmental Center: Establish care with a neurologist experienced in Rett syndrome.
3. Discuss Trofinetide (Daybue): Evaluate starting this approved drug to help improve communication and motor skills.
4. Implement Communication Aids: Introduce eye-gaze technology early to assist in building non-verbal communication methods.

❓ Patient FAQ

Q: Why does Rett syndrome primarily affect girls?
A: Rett syndrome is caused by a mutation in the **MECP2** gene, which is located on the X chromosome. Girls have two X chromosomes, so if one has the mutation, they have a second, healthy X chromosome to help them survive (though the mutated gene still causes severe symptoms). Boys only have one X chromosome. If a boy inherits the mutated MECP2 gene, they do not have a backup copy, which is typically fatal before birth or shortly after.

Q: What is the cause of the constant hand-wringing in Rett syndrome?
A: The hand wringing, washing, or clapping is a "stereotypy"—an involuntary, repetitive movement. The MECP2 mutation damages the development of the brain pathways that control voluntary motor planning and movement. As a result, children lose the ability to use their hands for voluntary tasks (like holding a toy), and the brain default-signals these continuous, repetitive stereotypic movements instead.